Form 4: Rhythm Pharmaceuticals Director Lynn A. Tetrault Reports Stock Transactions
SEC Filing
Director Lynn A. Tetrault reports the vesting and conversion of restricted stock units into Rhythm Pharmaceuticals common stock.
Summary
- On June 21, 2024, Lynn A. Tetrault, a director of Rhythm Pharmaceuticals, reported a transaction involving restricted stock units.
- 3,000 restricted stock units vested and were converted into 3,000 shares of Rhythm Pharmaceuticals common stock.
- The transaction was reported on a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company director, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects the standard vesting of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of transaction: vesting and conversion of restricted stock units. |
| 06/25/2024 | Date of report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.